NIH-funded research NIH-funded research

Pulmonary embolism: catheter-directed clot removal for better outcomes

Official title: 2/2 Pulmonary Embolism: Thrombus Removal with Catheter-Directed Therapy (PE-TRACT Trial) –DCC

Funded at New York University School of Medicine · NIH-11384861 · Data updated 2026-11-12

This trial tests whether delivering clot-dissolving medication directly to the lungs via a catheter helps people with submassive pulmonary embolism feel better and function better, with fewer bleeding risks.

More Pulmonary Embolism research and trials

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionNew York University School of Medicine
NIH-funded
Lab location1 site (New York, United States)
Project startSeptember 1, 2022
Project endAugust 31, 2028
Funding year2026
Award (this year)$553,838
NIH project number5U24HL155811-05
Project IDNIH-11384861 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates are adults with submassive pulmonary embolism and right heart dysfunction but without low blood pressure.

Less likely to help

Patients with different types of PE, very high bleeding risk, or contraindications to catheter procedures may not benefit from CDT.

What this research studies

If you have submassive PE with right heart strain but stable blood pressure, this study looks at catheter-directed therapy as an alternative to standard care. Participants are randomly assigned to receive CDT or not, and the study includes careful monitoring of heart and lung function over time. The trial is designed to adapt as results come in, with measurements focused on short-term fitness and long-term daily function. It’s conducted at New York University School of Medicine and aims to enroll up to 500 patients. The researchers will compare outcomes such as peak oxygen use at 3 months and NYHA class at 12 months to determine if CDT offers meaningful benefits with acceptable safety.

Why it matters

Potential benefit: If CDT proves more beneficial, patients with submassive PE could have better heart-lung health and daily function with potentially lower bleeding risk.

How similar studies have gone: Previous trials suggest potential benefits of targeted therapy, but definitive long-term improvements remain to be proven in this adaptive trial.

Where this research is happening

  • New York University School of Medicine
    New York, United States
    Active

Researchers

  • Principal investigator: Troxel, Andrea B — New York University School of Medicine
  • Study coordinator: Troxel, Andrea B

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.